Enhertu Gains Approval in China as First HER2-Directed Therapy for HER2-Mutant Metastatic Non-Small Cell Lung Cancer Read more
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation Read more
Boehringer Ingelheim and Circle Pharma announce new research collaboration to develop a novel precision cancer treatment Read more
Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies Read more
Biogen Secures FDA Breakthrough Therapy Designation for Felzartamab to Combat Antibody-Mediated Rejection in Kidney Transplants Read more
insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases Read more
Boehringer receives FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide Read more